Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.

Recessive dystrophic epidermolysis bullosa (RDEB) is an autosomal recessive disorder characterized by the loss of collagen type VII, an intrinsic component of the anchoring fibrils, which attach the epidermis to the dermis. Of the genetic blistering disorders, RDEB has the highest rate of morbidity and mortality, with morbidity arising from fusion of digits in a mitten-glove deformity and growth retardation associated with anemia. The leading cause of death in RDEB is cutaneous squamous cell carcinoma, which causes death through invasion and metastasis. In order to better understand the pathogenesis of these rare but aggressive squamous cell carcinoma (SCC), we analyzed them for mutations in p53 and loss of p16ink4a. Three tumors demonstrated mutations in the p53 tumor suppressor gene. We also analyzed SCC from patients with RDEB for the presence of p16ink4a hypermethylation, and found two tumors that have loss of p16ink4a through hypermethylation. This is the first description of specific abnormalities in tumor suppressor genes in RDEB associated SCC, and demonstrates that alterations in both p53 and p16ink4a can contribute to RDEB associated SCC.

[1]  J. Arbiser.  Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. , 2004, Seminars in cancer biology.

[2]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[3]  B. Smoller,et al.  Analysis of Promoter Hypermethylation of Death-Associated Protein Kinase and p16 Tumor Suppressor Genes in Actinic Keratoses and Squamous Cell Carcinomas of the Skin , 2003, Modern Pathology.

[4]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[5]  D. Zakarya,et al.  Structure–cytotoxicity relationships for a series of HEPT derivatives , 2002, Journal of molecular modeling.

[6]  D. Sidransky,et al.  O6-Methylguanine-DNA Methyltransferase Promoter Hypermethylation Shifts the p53 Mutational Spectrum in Non-Small Cell Lung Cancer , 2001 .

[7]  R. Kraft,et al.  COP9 signalosome‐specific phosphorylation targets p53 to degradation by the ubiquitin system , 2001, The EMBO journal.

[8]  C. Elmets,et al.  Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. , 2001, Journal of the American Academy of Dermatology.

[9]  J. Jen,et al.  Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.

[10]  R. Franklin,et al.  Oxidative stress regulates the interaction of p16 with Cdk4. , 2000, Biochemical and biophysical research communications.

[11]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[12]  H. Kashiwazaki,et al.  Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. , 1999, Cancer research.

[13]  J. R. McMillan,et al.  Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. , 1999, The Journal of investigative dermatology.

[14]  J. Arbiser,et al.  Curcumin Is an In Vivo Inhibitor of Angiogenesis , 1998, Molecular medicine.

[15]  J. Folkman,et al.  Basic Fibroblast Growth Factor: A Missing Link between Collagen VII, Increased Collagenase, and Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa , 1998, Molecular medicine.

[16]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[17]  A. Balmain,et al.  Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. , 1995, Cancer research.

[18]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[19]  J. Uitto,et al.  Point mutations in the regions of the COL7A1 gene coding for the NC-1 and NC-2 domains of collagen VII in patients with recessive epidermolysis bullosa dystrophica (R-EBD) , 1994 .

[20]  C. Purdie,et al.  A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. , 1994, Oncogene.

[21]  A. Ziegler,et al.  Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[23]  J. Arbiser,et al.  Reactive Oxygen-induced Carcinogenesis Causes Hypermethylation of p16Ink4a and Activation of MAP Kinase , 2002, Molecular medicine.

[24]  J. McGrath,et al.  Metastatic squamous cell carcinoma resembling angiosarcoma complicating dystrophic epidermolysis bullosa. , 1991, Dermatologica.

[25]  A. Gottlieb,et al.  Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis. , 1990 .

[26]  R. Wakeel,et al.  Death from metastatic, cutaneous, squamous cell carcinoma in autosomal recessive dystrophic epidermolysis bullosa despite permanent inpatient care. , 1988, Dermatologica.